Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Related Posts

Incyte gets grant for treatment of various cancers usin...

Apr 5, 2024

FDA approves Analog and Dipharma’s ANDA for nitisinone ...

Jun 1, 2023

EMA’s CHMP recommends Bristol Myers Squibb’s Breyanzi a...

Apr 3, 2023